MAPT and Alzheimer disease: Revised diagnostic criteria for AD introduced in 2011 emphasized the use of medical imaging to identify objective signs of the disease in the brain, such as amyloid-beta (Aβ) or tau-specific positron emission tomography (PET) imaging (7, 8).